Arikace is a pulmonary delivered liposomal drug therapy to target Pseudomonas infections in cystic fibrosis patients.
more
Arikace
Facts from the Community
From the BioVenturist base
Indication or disease:
| Disease | Phase of development |
|---|---|
Delivery Technology:
Technology involved:
Developed by:
We can tell you that Arikace is a…
If you know more about Arikace, you can add more facts here »
You can help improve this topic by adding more facts here
